NCT06537726 Breath Analysis for the Detection of Invasive Fungal Infections
| NCT ID | NCT06537726 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2024-08-19 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2024-08-19 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity. With the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of acute leukemia * Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer * Neutropenia (\<500/µl) present at inclusion or planned chemotherapy with expected neutropenia (\<500/µl) for more than 7 days Exclusion Criteria: * Unable to follow instructions for breath analysis * Anatomic abnormalities precluding the use of a mouthpiece for breath analysis
Contact & Investigator
Jeremy Deuel, PD Dr.
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT06537726 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06537726 currently recruiting?
Yes, NCT06537726 is actively recruiting participants. Contact the research team at jeremy.deuel@usz.ch for enrollment information.
Where is the NCT06537726 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT06537726 clinical trial?
NCT06537726 is sponsored by University of Zurich. The principal investigator is Jeremy Deuel, PD Dr. at University of Zurich. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.